Vaccine-induced enhancement of viral infections

Vaccine

Volumn 27, Issue 4, 2009, Pages 505-512

  Huisman, W ^a   Martina, B E E ^a   Rimmelzwaan, G F ^a   Gruters, R A ^a   Osterhaus, A D M E ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

ADE; Enhancement; HIV; Lentivirus; Vaccine

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; ISCOM; VARICELLA ZOSTER VACCINE; VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY DEPENDENT ENHANCEMENT; ANTIBODY RESPONSE; CELLULAR IMMUNITY; CORONAVIRUS; DENGUE VIRUS; FELINE IMMUNODEFICIENCY VIRUS; FLAVIVIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION SENSITIVITY; JAPANESE ENCEPHALITIS VIRUS; MURRAY VALLEY ENCEPHALITIS VIRUS; NONHUMAN; PARAMYXOVIRUS; PRIORITY JOURNAL; RETROVIRUS INFECTION; REVIEW; VIRUS INFECTION; VIRUS PATHOGENESIS; WEST NILE FLAVIVIRUS;

ANIMALS; DISEASE SUSCEPTIBILITY; HIV-1; HUMANS; IMMUNITY, CELLULAR; LENTIVIRUS INFECTIONS; VIRAL VACCINES; VIRUS DISEASES; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 57749205619     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.10.087     Document Type: Review

References (128)

1. Cohen M.S., Hellmann N., Levy J.A., DeCock K., and Lange J. The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. J Clin Invest 118 Apr (4) (2008) 1244-1254
2. VandeWoude S., and Apetrei C. Going wild: lessons from naturally occurring T-lymphotropic lentiviruses. Clin Microbiol Rev 19 Oct (4) (2006) 728-762
3. Takada A., and Kawaoka Y. Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev Med Virol 13 Nov-Dec (6) (2003) 387-398
4. Hawkes R.A. Enhancement of the infectivity of arboviruses by specific antisera produced in domestic fowls. Aust J Exp Biol Med Sci 42 Aug (1964) 465-482
5. Halstead S.B., and O'Rourke E.J. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med 146 Jul (1) (1977) 201-217
6. Halstead S.B., O'Rourke E.J., and Allison A.C. Dengue viruses and mononuclear phagocytes. II. Identity of blood and tissue leukocytes supporting in vitro infection. J Exp Med 146 Jul (1) (1977) 218-229
7. Halstead S.B. Immune enhancement of viral infection. Prog Allergy 31 (1982) 301-364
8. Burke D.S., and Kliks S. Antibody-dependent enhancement in dengue virus infections. J Infect Dis 193 Feb (4) (2006) 601-603 author reply 3-4
9. Graham R.R., Juffrie M., Tan R., Hayes C.G., Laksono I., Ma'roef C., et al. A prospective seroepidemiologic study on dengue in children four to nine years of age in Yogyakarta. Indonesia I. studies in 1995-1996. Am J Trop Med Hyg 61 Sep (3) (1999) 412-419
10. Kliks S.C., Nimmanitya S., Nisalak A., and Burke D.S. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 38 Mar (2) (1988) 411-419
11. Kliks S.C., Nisalak A., Brandt W.E., Wahl L., and Burke D.S. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 40 Apr (4) (1989) 444-451
12. Sangkawibha N., Rojanasuphot S., Ahandrik S., Viriyapongse S., Jatanasen S., Salitul V., et al. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980, outbreak. Am J Epidemiol 120 Nov (5) (1984) 653-669
13. Halstead S.B., Shotwell H., and Casals J. Studies on the pathogenesis of dengue infection in monkeys. I. Clinical laboratory responses to primary infection. J Infect Dis 128 Jul (1) (1973) 7-14
14. Boonnak K., Slike B.M., Burgess T.H., Mason R.M., Wu S.J., Sun P., et al. Role of dendritic cells in antibody-dependent enhancement of dengue virus infection. J Virol 82 Apr (8) (2008) 3939-3951
15. Brown M.G., King C.A., Sherren C., Marshall J.S., and Anderson R. A dominant role for FcgammaRII in antibody-enhanced dengue virus infection of human mast cells and associated CCL5 release. J Leukoc Biol 80 Dec (6) (2006) 1242-1250
16. Littaua R., Kurane I., and Ennis F.A. Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection. J Immunol 144 Apr (8) (1990) 3183-3186
17. Rodrigo W.W., Jin X., Blackley S.D., Rose R.C., and Schlesinger J.J. Differential enhancement of dengue virus immune complex infectivity mediated by signaling-competent and signaling-incompetent human Fcgamma RIA (CD64) or FcgammaRIIA (CD32). J Virol 80 Oct (20) (2006) 10128-10138
18. Schlesinger J.J., and Chapman S.E. Influence of the human high-affinity IgG receptor FcgammaRI (CD64) on residual infectivity of neutralized dengue virus. Virology 260 Jul (1) (1999) 84-88
19. Libraty D.H., Endy T.P., Houng H.S., Green S., Kalayanarooj S., Suntayakorn S., et al. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis 185 May (9) (2002) 1213-1221
20. Vaughn D.W., Green S., Kalayanarooj S., Innis B.L., Nimmannitya S., Suntayakorn S., et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 181 Jan (1) (2000) 2-9
21. Wang W.K., Chao D.Y., Kao C.L., Wu H.C., Liu Y.C., Li C.M., et al. High levels of plasma dengue viral load during defervescence in patients with dengue hemorrhagic fever: implications for pathogenesis. Virology 305 Jan (2) (2003) 330-338
22. Chareonsirisuthigul T., Kalayanarooj S., and Ubol S. Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells. J Gen Virol 88 Feb (Pt 2) (2007) 365-375
23. Lidbury B.A., and Mahalingam S. Specific ablation of antiviral gene expression in macrophages by antibody-dependent enhancement of Ross River virus infection. J Virol 74 Sep (18) (2000) 8376-8381
24. Mahalingam S., and Lidbury B.A. Suppression of lipopolysaccharide-induced antiviral transcription factor (STAT-1 and NF-kappa B) complexes by antibody-dependent enhancement of macrophage infection by Ross River virus. Proc Natl Acad Sci USA 99 Oct (21) (2002) 13819-13824
25. Hartmann K. Feline infectious peritonitis. Vet Clin North Am Small Anim Pract 35 Jan (1) (2005) 39-79 vi
26. Weiss R.C., and Scott F.W. Antibody-mediated enhancement of disease in feline infectious peritonitis: comparisons with dengue hemorrhagic fever. Comp Immunol Microbiol Infect Dis 4 2 (1981) 175-189
27. Vennema H., de Groot R.J., Harbour D.A., Dalderup M., Gruffydd-Jones T., Horzinek M.C., et al. Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization. J Virol 64 Mar (3) (1990) 1407-1409
28. Corapi W.V., Olsen C.W., and Scott F.W. Monoclonal antibody analysis of neutralization and antibody-dependent enhancement of feline infectious peritonitis virus. J Virol 66 Nov (11) (1992) 6695-6705
29. Hohdatsu T., Nakamura M., Ishizuka Y., Yamada H., and Koyama H. A study on the mechanism of antibody-dependent enhancement of feline infectious peritonitis virus infection in feline macrophages by monoclonal antibodies. Arch Virol 120 3-4 (1991) 207-217
30. Olsen C.W., Corapi W.V., Ngichabe C.K., Baines J.D., and Scott F.W. Monoclonal antibodies to the spike protein of feline infectious peritonitis virus mediate antibody-dependent enhancement of infection of feline macrophages. J Virol 66 Feb (2) (1992) 956-965
31. Polack F.P. Atypical measles and enhanced respiratory syncytial virus disease (ERD) made simple. Pediatr Res 62 Jul (1) (2007) 111-115
32. Murphy B.R., Prince G.A., Walsh E.E., Kim H.W., Parrott R.H., Hemming V.G., et al. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol 24 Aug (2) (1986) 197-202
33. Murphy B.R., and Walsh E.E. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol 26 Aug (8) (1988) 1595-1597
34. Delgado M.F., and Polack F.P. Involvement of antibody, complement and cellular immunity in the pathogenesis of enhanced respiratory syncytial virus disease. Expert Rev Vaccines 3 Dec (6) (2004) 693-700
35. Openshaw P.J., and Tregoning J.S. Immune responses and disease enhancement during respiratory syncytial virus infection. Clin Microbiol Rev 18 Jul (3) (2005) 541-555
36. Moghaddam A., Olszewska W., Wang B., Tregoning J.S., Helson R., Sattentau Q.J., et al. A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat Med 12 Aug (8) (2006) 905-907
37. de Swart R.L., van den Hoogen B.G., Kuiken T., Herfst S., van Amerongen G., Yuksel S., et al. Immunization of macaques with formalin-inactivated human metapneumovirus induces hypersensitivity to hMPV infection. Vaccine 25 Dec (51) (2007) 8518-8528
38. Hosie M.J., Osborne R., Reid G., Neil J.C., and Jarrett O. Enhancement after feline immunodeficiency virus vaccination. Vet Immunol Immunopathol 35 Dec (1-2) (1992) 191-197
39. Lombardi S., Garzelli C., Pistello M., Massi C., Matteucci D., Baldinotti F., et al. A neutralizing antibody-inducing peptide of the V3 domain of feline immunodeficiency virus envelope glycoprotein does not induce protective immunity. J Virol 68 Dec (12) (1994) 8374-8379
40. Siebelink K.H., Tijhaar E., Huisman R.C., Huisman W., de Ronde A., Darby I.H., et al. Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines. J Virol 69 Jun (6) (1995) 3704-3711
41. Hammond S.A., Raabe M.L., Issel C.J., and Montelaro R.C. Evaluation of antibody parameters as potential correlates of protection or enhancement by experimental vaccines to equine infectious anemia virus. Virology 262 Sep (2) (1999) 416-430
42. Issel C.J., Horohov D.W., Lea D.F., Adams Jr. W.V., Hagius S.D., McManus J.M., et al. Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus. J Virol 66 Jun (6) (1992) 3398-3408
43. Raabe M.L., Issel C.J., Cook S.J., Cook R.F., Woodson B., and Montelaro R.C. Immunization with a recombinant envelope protein (rgp90) of EIAV produces a spectrum of vaccine efficacy ranging from lack of clinical disease to severe enhancement. Virology 245 May (1) (1998) 151-162
44. Raabe M.L., Issel C.J., and Montelaro R.C. In vitro antibody-dependent enhancement assays are insensitive indicators of in vivo vaccine enhancement of equine infectious anemia virus. Virology 259 Jul (2) (1999) 416-427
45. Wang S.Z., Rushlow K.E., Issel C.J., Cook R.F., Cook S.J., Raabe M.L., et al. Enhancement of EIAV replication and disease by immunization with a baculovirus-expressed recombinant envelope surface glycoprotein. Virology 199 Feb (1) (1994) 247-251
46. Robinson Jr. W.E., Montefiori D.C., and Mitchell W.M. Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. Lancet 1 Apr (8589) (1988) 790-794
47. Takeda A., Tuazon C.U., and Ennis F.A. Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science 242 Oct (4878) (1988) 580-583
48. Homsy J., Meyer M., Tateno M., Clarkson S., and Levy J.A. The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells. Science 244 Jun (4910) (1989) 1357-1360
49. Fust G. Enhancing antibodies in HIV infection. Parasitology 115 Suppl (1997) S127-S140
50. Sullivan N.J. Antibody-mediated enhancement of viral disease. Curr Top Microbiol Immunol 260 (2001) 145-169
51. Perno C.F., Baseler M.W., Broder S., and Yarchoan R. Infection of monocytes by human immunodeficiency virus type 1 blocked by inhibitors of CD4-gp120 binding, even in the presence of enhancing antibodies. J Exp Med 171 Apr (4) (1990) 1043-1056
52. Takeda A., Sweet R.W., and Ennis F.A. Two receptors are required for antibody-dependent enhancement of human immunodeficiency virus type 1 infection: CD4 and Fc gamma R. J Virol 64 Nov (11) (1990) 5605-5610
53. Trischmann H., Davis D., and Lachmann P.J. Lymphocytotropic strains of HIV type 1 when complexed with enhancing antibodies can infect macrophages via Fc gamma RIII, independently of CD4. AIDS Res Hum Retroviruses 11 Mar (3) (1995) 343-352
54. Daeron M. Structural bases of Fc gamma R functions. Int Rev Immunol 16 1-2 (1997) 1-27
55. Schutten M., Andeweg A.C., Bosch M.L., and Osterhaus A.D. Enhancement of infectivity of a non-syncytium inducing HIV-1 by sCD4 and by human antibodies that neutralize syncytium inducing HIV-1. Scand J Immunol 41 Jan (1) (1995) 18-22
56. Sullivan N., Sun Y., Li J., Hofmann W., and Sodroski J. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J Virol 69 Jul (7) (1995) 4413-4422
57. Guillon C., Schutten M., Boers P.H., Gruters R.A., and Osterhaus A.D. Antibody-mediated enhancement of human immunodeficiency virus type 1 infectivity is determined by the structure of gp120 and depends on modulation of the gp120-CCR5 interaction. J Virol 76 Mar (6) (2002) 2827-2834
58. Sullivan N., Sun Y., Binley J., Lee J., Barbas III C.F., et al. Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies. J Virol 72 Aug (8) (1998) 6332-6338
59. Wojtowicz W.M., Farzan M., Joyal J.L., Carter K., Babcock G.J., Israel D.I., et al. Stimulation of enveloped virus infection by beta-amyloid fibrils. J Biol Chem 277 Sep (38) (2002) 35019-35024
60. Munch J., Rucker E., Standker L., Adermann K., Goffinet C., Schindler M., et al. Semen-derived amyloid fibrils drastically enhance HIV infection. Cell 131 Dec (6) (2007) 1059-1071
61. Le Grand R., Vogt G., Chapel A., and Dormont D. Antibody-dependent enhancement and neutralization pattern of sera from SIV-infected or HIV-2-vaccinated rhesus monkeys. J Med Primatol 20 Jun (4) (1991) 172-176
62. Montefiori D.C., Robinson Jr. W.E., Hirsch V.M., Modliszewski A., Mitchell W.M., and Johnson P.R. Antibody-dependent enhancement of SIV infection: further characterization and cross reactivity between macaque and sooty mangabey isolates. J Med Primatol 19 3-4 (1990) 269-278
63. Robinson Jr. W.E., Montefiori D.C., Gillespie D.H., and Mitchell W.M. Complement-mediated, antibody-dependent enhancement of HIV-1 infection in vitro is characterized by increased protein and RNA syntheses and infectious virus release. J Acquir Immune Defic Syndr 2 1 (1989) 33-42
64. Wu S.C., Spouge J.L., Conley S.R., Tsai W.P., Merges M.J., and Nara P.L. Human plasma enhances the infectivity of primary human immunodeficiency virus type 1 isolates in peripheral blood mononuclear cells and monocyte-derived macrophages. J Virol 69 Oct (10) (1995) 6054-6062
65. Wahl S.M., Greenwell-Wild T., Peng G., Hale-Donze H., and Orenstein J.M. Co-infection with opportunistic pathogens promotes human immunodeficiency virus type 1 infection in macrophages. J Infect Dis 179 May (Suppl 3) (1999) S457-S460
66. Orenstein J.M., Fox C., and Wahl S.M. Macrophages as a source of HIV during opportunistic infections. Science 276 Jun (5320) (1997) 1857-1861
67. Wahl S.M., and Orenstein J.M. Immune stimulation and HIV-1 viral replication. J Leukoc Biol 62 Jul (1) (1997) 67-71
68. van der Ende M.E., Schutten M., Raschdorff B., Grossschupff G., Racz P., Osterhaus A.D., et al. CD4 T cells remain the major source of HIV-1 during end stage disease. Aids 13 Jun (9) (1999) 1015-1019
69. Thibault S., Tardif M.R., Barat C., and Tremblay M.J. TLR2 signaling renders quiescent naive and memory CD4+ T cells more susceptible to productive infection with X4 and R5 HIV-type 1. J Immunol 179 Oct (7) (2007) 4357-4366
70. Palu G., Benetti L., and Calistri A. Molecular basis of the interactions between herpes simplex viruses and HIV-1. Herpes 8 Jul (2) (2001) 50-55
71. Bertram S., Hufert F.T., van Lunzen J., and von Laer D. Coinfection of individual leukocytes with human cytomegalovirus and human immunodeficiency virus is a rare event in vivo. J Med Virol 49 Aug (4) (1996) 283-288
72. Staprans S.I., Hamilton B.L., Follansbee S.E., Elbeik T., Barbosa P., Grant R.M., et al. Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med 182 Dec (6) (1995) 1727-1737
73. Stanley S.K., Ostrowski M.A., Justement J.S., Gantt K., Hedayati S., Mannix M., et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 334 May (19) (1996) 1222-1230
74. Vigano A., Bricalli D., Trabattoni D., Salvaggio A., Ruzzante S., Barbi M., et al. Immunization with both T cell-dependent and T cell-independent vaccines augments HIV viral load secondarily to stimulation of tumor necrosis factor alpha. AIDS Res Hum Retroviruses 14 Jun (9) (1998) 727-734
75. Fowke K.R., D'Amico R., Chernoff D.N., Pottage Jr. J.C., Benson C.A., Sha B.E., et al. Immunologic and virologic evaluation after influenza vaccination of HIV-1-infected patients. Aids 11 Jul (8) (1997) 1013-1021
76. Dieye T.N., Sow P.S., Simonart T., Gueye-Ndiaye A., Popper S.J., Delforge M.L., et al. Immunologic and virologic response after tetanus toxoid booster among HIV-1- and HIV-2-infected Senegalese individuals. Vaccine 20 Dec (5-6) (2001) 905-913
77. Villinger F., Rowe T., Parekh B.S., Green T.A., Mayne A.E., Grimm B., et al. Chronic immune stimulation accelerates SIV-induced disease progression. J Med Primatol 30 Oct (5) (2001) 254-259
78. Rizzuto C.D., and Sodroski J.G. Contribution of virion ICAM-1 to human immunodeficiency virus infectivity and sensitivity to neutralization. J Virol 71 Jun (6) (1997) 4847-4851
79. Hioe C.E., Bastiani L., Hildreth J.E., and Zolla-Pazner S. Role of cellular adhesion molecules in HIV type 1 infection and their impact on virus neutralization. AIDS Res Hum Retroviruses 14 Oct (Suppl 3) (1998) S247-S254
80. Bounou S., Leclerc J.E., and Tremblay M.J. Presence of host ICAM-1 in laboratory and clinical strains of human immunodeficiency virus type 1 increases virus infectivity and CD4 (+)-T-cell depletion in human lymphoid tissue, a major site of replication in vivo. J Virol 76 Feb (3) (2002) 1004-1014
81. Barton E.S., White D.W., Cathelyn J.S., Brett-McClellan K.A., Engle M., Diamond M.S., et al. Herpesvirus latency confers symbiotic protection from bacterial infection. Nature 447 May (7142) (2007) 326-329
82. Maheshwari A., Smythies L.E., Wu X., Novak L., Clements R., Eckhoff D., et al. Cytomegalovirus blocks intestinal stroma-induced down-regulation of macrophage HIV-1 infection (2006) 1111-1117
83. Montaner L.J., Crowe S.M., Aquaro S., Perno C.-F., Stevenson M., and Collman R.G. Advances in macrophage and dendritic cell biology in HIV-1 infection stress key understudied areas in infection, pathogenesis, and analysis of viral reservoirs. J Leukoc Biol (2006) 961-964
84. Geijtenbeek T.B., Kwon D.S., Torensma R., van Vliet S.J., van Duijnhoven G.C., Middel J., et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100 Mar (5) (2000) 587-597
85. de Witte L., Nabatov A., and Geijtenbeek T.B. Distinct roles for DC-SIGN+-dendritic cells and Langerhans cells in HIV-1 transmission. Trends Mol Med 14 Jan (1) (2008) 12-19
86. Geijtenbeek T.B., and van Kooyk Y. DC-SIGN, a novel HIV receptor on DCs that mediates HIV-1 transmission. Curr Top Microbiol Immunol 276 (2003) 31-54
87. Bakri Y., Schiffer C., Zennou V., Charneau P., Kahn E., Benjouad A., et al. The maturation of dendritic cells results in postintegration inhibition of HIV-1 replication. J Immunol 166 Mar (6) (2001) 3780-3788
88. Dong C., Janas A.M., Wang J.H., Olson W.J., and Wu L. Characterization of human immunodeficiency virus type 1 replication in immature and mature dendritic cells reveals dissociable cis- and trans-infection. J Virol 81 Oct (20) (2007) 11352-11362
89. Granelli-Piperno A., Delgado E., Finkel V., Paxton W., and Steinman R.M. Immature dendritic cells selectively replicate macrophagetropic (M-tropic) human immunodeficiency virus type 1, while mature cells efficiently transmit both M- and T-tropic virus to T cells. J Virol 72 Apr (4) (1998) 2733-2737
90. Izquierdo-Useros N., Blanco J., Erkizia I., Fernandez-Figueras M.T., Borras F.E., Naranjo-Gomez M., et al. Maturation of blood-derived dendritic cells enhances human immunodeficiency virus type 1 capture and transmission. J Virol 81 Jul (14) (2007) 7559-7570
91. Boggiano C., Manel N., and Littman D.R. Dendritic cell-mediated trans-enhancement of human immunodeficiency virus type 1 infectivity is independent of DC-SIGN. J Virol 81 Mar (5) (2007) 2519-2523
92. Pedersen N.C., Ho E.W., Brown M.L., and Yamamoto J.K. Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science 235 Feb (4790) (1987) 790-793
93. Uhl E.W., Heaton-Jones T.G., Pu R., and Yamamoto J.K. FIV vaccine development and its importance to veterinary and human medicine: a review FIV vaccine 2002, update and review. Vet Immunol Immunopathol 90 Dec (3-4) (2002) 113-132
94. Uhl E.W., Martin M., Coleman J.K., and Yamamoto J.K. Advances in FIV vaccine technology. Vet Immunol Immunopathol 123 May (1-2) (2008) 65-80
95. Elyar J.S., Tellier M.C., Soos J.M., and Yamamoto J.K. Perspectives on FIV vaccine development. Vaccine 15 Aug-Sep (12-13) (1997) 1437-1444
96. Yamamoto J.K., Pu R., Sato E., and Hohdatsu T. Feline immunodeficiency virus pathogenesis and development of a dual-subtype feline-immunodeficiency-virus vaccine. Aids 21 Mar (5) (2007) 547-563
97. Dunham S.P., Bruce J., Klein D., Flynn J.N., Golder M.C., MacDonald S., et al. Prime-boost vaccination using DNA and whole inactivated virus vaccines provides limited protection against virulent feline immunodeficiency virus. Vaccine 24 Nov (49-50) (2006) 7095-7108
98. Huisman W., Schrauwen E.J., Pas S.D., Karlas J.A., Rimmelzwaan G.F., and Osterhaus A.D. Antibodies specific for hypervariable regions 3 to 5 of the feline immunodeficiency virus envelope glycoprotein are not solely responsible for vaccine-induced acceleration of challenge infection in cats. J Gen Virol 85 Jul (Pt 7) (2004) 1833-1841
99. Karlas J.A., Siebelink K.H., Peer M.A., Huisman W., Cuisinier A.M., Rimmelzwaan G.F., et al. Vaccination with experimental feline immunodeficiency virus vaccines, based on autologous infected cells, elicits enhancement of homologous challenge infection. J Gen Virol 80 Mar (Pt 3) (1999) 761-765
100. Giannecchini S., Isola P., Sichi O., Matteucci D., Pistello M., Zaccaro L., et al. AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: failure to protect and possible enhancement of challenge infection by four cell-based vaccines prepared with autologous lymphoblasts. J Virol 76 Jul (14) (2002) 6882-6892
101. Richardson J., Moraillon A., Baud S., Cuisinier A.M., Sonigo P., and Pancino G. Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope. J Virol 71 Dec (12) (1997) 9640-9649
102. Richardson J., Broche S., Baud S., Leste-Lasserre T., Femenia F., Levy D., et al. Lymphoid activation: a confounding factor in AIDS vaccine development?. J Gen Virol 83 Oct (Pt 10) (2002) 2515-2521
103. Schwartz D.H. Potential pitfalls on the road to an effective HIV vaccine. Immunol Today 15 Feb (2) (1994) 54-57
104. Douek D.C., Brenchley J.M., Betts M.R., Ambrozak D.R., Hill B.J., Okamoto Y., et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 417 May (6884) (2002) 95-98
105. Shimojima M., Miyazawa T., Ikeda Y., McMonagle E.L., Haining H., Akashi H., et al. Use of CD134 as a primary receptor by the feline immunodeficiency virus. Science 303 Feb (5661) (2004) 1192-1195
106. Willett B.J., McMonagle E.L., Ridha S., and Hosie M.J. Differential utilization of CD134 as a functional receptor by diverse strains of feline immunodeficiency virus. J Virol 80 Apr (7) (2006) 3386-3394
107. Dean G.A., Reubel G.H., Moore P.F., and Pedersen N.C. Proviral burden and infection kinetics of feline immunodeficiency virus in lymphocyte subsets of blood and lymph node. J Virol 70 Aug (8) (1996) 5165-5169
108. English R.V., Johnson C.M., Gebhard D.H., and Tompkins M.B. In vivo lymphocyte tropism of feline immunodeficiency virus. J Virol 67 Sep (9) (1993) 5175-5186
109. de Parseval A., Chatterji U., Sun P., and Elder J.H. Feline immunodeficiency virus targets activated CD4+ T cells by using CD134 as a binding receptor. Proc Natl Acad Sci USA 101 Aug (35) (2004) 13044-13049
110. Willett B.J., Picard L., Hosie M.J., Turner J.D., Adema K., and Clapham P.R. Shared usage of the chemokine receptor CXCR4 by the feline and human immunodeficiency viruses. J Virol 71 Sep (9) (1997) 6407-6415
111. de Parseval A., Ngo S., Sun P., and Elder J.H. Factors that increase the effective concentration of CXCR4 dictate feline immunodeficiency virus tropism and kinetics of replication. J Virol 78 Sep (17) (2004) 9132-9143
112. Troth S.P., Dean A.D., and Hoover E.A. In vivo CXCR4 expression, lymphoid cell phenotype, and feline immunodeficiency virus infection. Vet Immunol Immunopathol 123 May (1-2) (2008) 97-105
113. Willett B.J., and Hosie M.J. Chemokine receptors and co-stimulatory molecules: unravelling feline immunodeficiency virus infection. Vet Immunol Immunopathol 123 May (1-2) (2008) 56-64
114. Sprague W.S., Robbiani M., Avery P.R., O'Halloran K.P., and Hoover E.A. Feline immunodeficiency virus dendritic cell infection and transfer. J Gen Virol 89 Mar (Pt 3) (2008) 709-715
115. van der Meer F.J., Schuurman N.M., Balzarini J., and Egberink H.F. Comparative evaluation of the activity of antivirals towards feline immunodeficiency virus in different cell culture systems. Antiviral Res 76 Nov (2) (2007) 198-201
116. Cameron P.U., Freudenthal P.S., Barker J.M., Gezelter S., Inaba K., and Steinman R.M. Dendritic cells exposed to human immunodeficiency virus type-1 transmit a vigorous cytopathic infection to CD4+ T cells. Science 257 Jul (5068) (1992) 383-387
117. Zhang Z., Schuler T., Zupancic M., Wietgrefe S., Staskus K.A., Reimann K.A., et al. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science 286 Nov (5443) (1999) 1353-1357
118. de Parseval A., Su S.V., Elder J.H., and Lee B. Specific interaction of feline immunodeficiency virus surface glycoprotein with human DC-SIGN. J Virol 78 Mar (5) (2004) 2597-2600
119. Reggeti F., Ackerley C., and Bienzle D. CD134 and CXCR4 expression corresponds to feline immunodeficiency virus infection of lymphocytes, macrophages and dendritic cells. J Gen Virol 89 Jan (Pt 1) (2008) 277-287
120. Staprans S.I., Barry A.P., Silvestri G., Safrit J.T., Kozyr N., Sumpter B., et al. Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. Proc Natl Acad Sci USA 101 Aug (35) (2004) 13026-13031
121. Mueller Y.M., Do D.H., Altork S.R., Artlett C.M., Gracely E.J., Katsetos C.D., et al. IL-15 treatment during acute simian immunodeficiency virus (SIV) infection increases viral set point and accelerates disease progression despite the induction of stronger SIV-specific CD8+ T cell responses. J Immunol 180 Jan (1) (2008) 350-360
122. Matano T., Kano M., Odawara T., Nakamura H., Takeda A., Mori K., et al. Induction of protective immunity against pathogenic simian immunodeficiency virus by a foreign receptor-dependent replication of an engineered avirulent virus. Vaccine 18 Aug (28) (2000) 3310-3318
123. Lun W.H., Takeda A., Nakamura H., Kano M., Mori K., Sata T., et al. Loss of virus-specific CD4 (+) T cells with increases in viral loads in the chronic phase after vaccine-based partial control of primary simian immunodeficiency virus replication in macaques. J Gen Virol 85 Jul (Pt 7) (2004) 1955-1963
124. Flynn N.M., Forthal D.N., Harro C.D., Judson F.N., Mayer K.H., Para M.F., et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 191 Mar (5) (2005) 654-665
125. Gilbert P.B., Peterson M.L., Follmann D., Hudgens M.G., Francis D.P., Gurwith M., et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 191 Mar (5) (2005) 666-677
126. Cohen J. AIDS research. Did Merck's failed HIV vaccine cause harm?. Science 318 Nov (5853) (2007) 1048-1049
127. Moore J.P., Klasse P.J., Dolan M.J., and Ahuja S.K. AIDS/HIV. A STEP into darkness or light?. Science 320 May (5877) (2008) 753-755
128. Gruters R., and Osterhaus A. AIDS vaccine research: consider co-infections. Science 319 Mar (5868) (2008) 1337